View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
December 23, 2019updated 12 Jul 2022 11:59am

Overview of industry-sponsored clinical trials in the UK, 2019

Novartis is the top sponsor, holding 4.9% of clinical trials, narrowly outnumbering AstraZeneca, which sponsored 4.6% of trials.

By GlobalData Healthcare

GlobalData analysed the number of industry-sponsored clinical trials in the UK with a start date between 1 January 2019 and 31 December 2019, the data was extracted on 17 December 2019. 

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

As displayed in Figure 1, the largest proportion of trials were in Phase III (40.3%), followed closely by Phase II trials (35.5%). Phase I clinical trials significantly outnumbered Phase IV studies, with 18.9% and 5.3% of trials respectively. Multinational trials (78.9%) significantly outnumbered single-country studies (21.1%), with the most striking variation seen in Phase III trials, where multinational studies hold a 99% greater proportion of Phase III studies. Phase I studies remain the only phase with a greater proportion of single-country trials; owing to their typically smaller size, this is not surprising. 

As shown in Figure 2, Novartis is the top sponsor, holding 4.9% of clinical trials, narrowly outnumbering AstraZeneca , which sponsored 4.6% of trials. Merck accounted for the third-highest proportion of trials (4.0%), followed by GlaxoSmithKline (3.3%), with Roche and Johnson & Johnson holding joint fifth place with each accounting for 2.9% of trials. 

Oncology is the most frequently investigated therapy area, accounting for the largest proportion of studies (25.8%); consequently, the top five indications are within the oncology therapeutic area. Solid tumours are the most researched indication, accounting for 5.5% of studies, followed by Non-Small Cell Lung Cancer (4.0%), Breast Cancer (3.1%), Prostate Cancer (2.6%), and Colorectal Cancer (2.4%). With the exclusion of solid tumours, the top indications mirror those of the most commonly occurring cancers in the UK as listed by Cancer Research UK, highlighting industry sponsors’ ability to target the largest indications with a potential to produce the most significant returns on investment. 

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Related Report
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena